

Serology assays used in SARS-CoV-2 seroprevalence surveys worldwide: a systematic review and meta-analysis of assay features, testing algorithms, and performance

Author list: Xiaomeng Ma^{1,2}, Zihan Li^{1,3}, Mairead G. Whelan¹, Dayoung Kim⁴, Christian Cao^{1,5}, Mercedes Yanes-Lane⁶, Tingting Yan^{1,5}, Thomas Jaenisch⁷, May Chu⁷, David A. Clifton⁶, Lorenzo Subissi⁸, Niklas Bobrovitz^{5,9}, Rahul K. Arora^{1,10*}

Affiliation:

1. Cumming School of Medicine, University of Calgary, Calgary, Alberta T2N 4N1, Canada
2. Institute of Health Policy Management and Evaluation, University of Toronto, Toronto, Ontario M5T 3M6, Canada
3. Wyss Institute for Biologically Inspired Engineering, University of California Berkeley, Berkeley, California 02115, USA
4. Faculty of Science, University of Calgary, Calgary, Alberta T2N 1N4, Canada
5. Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario M5S 1A8, Canada
6. COVID-19 Immunity Task Force, McGill University, Montreal, Quebec H3A 0G4, Canada
7. Department of Epidemiology & Center for Global Health, Colorado School of Public Health, Aurora, Colorado 80045, USA
8. World Health Organization, Geneva 1211, Switzerland
9. Department of Critical Care Medicine, University of Calgary, Calgary, Alberta T2N 4N1, Canada
10. Institute of Biomedical Engineering, University of Oxford, Oxford OX3 7DQ, UK

Key words:

Serological assay, seroprevalence, performance, sensitivity, specificity, evaluation, validation

Word count: 4159; **Abstract:** 297

1 **Abstract**

2 *Background:* Many serological assays to detect SARS-CoV-2 antibodies were developed during
3 the COVID-19 pandemic. Differences in the detection mechanism of SARS-CoV-2 serological
4 assays limited the comparability of seroprevalence estimates for populations being tested.

5 *Methods:* We conducted a systematic review and meta-analysis of serological assays used in
6 SARS-CoV-2 population seroprevalence surveys, searching for published articles, preprints,
7 institutional sources, and grey literature between January 1, 2020, and November 19, 2021. We
8 described features of all identified assays and mapped performance metrics by the
9 manufacturers, third-party head-to-head, and independent group evaluations. We compared the
10 reported assay performance by evaluation source with a mixed-effect beta regression model. A
11 simulation was run to quantify how biased assay performance affects population seroprevalence
12 estimates with test adjustment. *Results:* Among 1807 included serosurveys, 192 distinctive
13 commercial assays and 380 self-developed assays were identified. According to manufacturers,
14 28.6% of all commercial assays met WHO criteria for emergency use (sensitivity [Sn.] \geq
15 90.0%, specificity [Sp.] \geq 97.0%). However, manufacturers overstated the absolute values of
16 Sn. of commercial assays by 1.0% [0.1, 1.4%] and 3.3% [2.7, 3.4%], and Sp. by 0.9% [0.9,
17 0.9%] and 0.2% [-0.1, 0.4%] compared to third-party and independent evaluations, respectively.
18 Reported performance data was not sufficient to support a similar analysis for self-developed
19 assays. Simulations indicate that inaccurate Sn. and Sp. can bias seroprevalence estimates
20 adjusted for assay performance; the error level changes with the background seroprevalence.
21 *Conclusions:* The Sn. and Sp. of the serological assay are not fixed properties, but varying
22 features depending on the testing population. To achieve precise population estimates and to
23 ensure the comparability of seroprevalence, serosurveys should select assays with high

- 24 performance validated not only by their manufacturers and adjust seroprevalence estimates based
- 25 on assured performance data. More investigation should be directed to consolidating the
- 26 performance of self-developed assays.

27 **Introduction**

28 Serosurveys have been foundational to emergency pandemic surveillance and evidence-guided
29 public health policy during the COVID-19 pandemic. These studies help map the true extent of
30 SARS-CoV-2 infection, indicators of population humoral immunity, and other measures of
31 disease risk^[1]. Serological assays, the laboratory tools for detecting antibodies produced after
32 SARS-CoV-2 infection or vaccination, are a critical methodological step in serosurvey design
33 and result interpretation. In response to expanding demand for serosurveys, many SARS-CoV-2
34 serological assays were developed, mobilized, and adopted since the beginning of the pandemic.

35
36 The breadth of available serological assays since the beginning of the pandemic is large and
37 diverse, with over hundreds of serological assays currently commercially available. Most
38 serological assays target antibodies against the spike (S) and/or nucleocapsid (N) proteins^[2] of
39 the SARS-CoV-2 virus and detect a variety of antibody isotypes (IgG, IgM, IgA, or all - Total
40 Ab). To date, several types of analyte binding methods and virological techniques have been
41 applied to SARS-CoV-2 serology — the most common being neutralization assays, lateral flow
42 immunoassays [LFIA], immunofluorescence assays [IFAs], enzyme-linked immunosorbent
43 assays [ELISAs], and chemiluminescence assays [CLIAs].

44
45 An important consideration during serosurvey study design is assay performance. Assay
46 performance has direct consequences on the validity of a study, where the sensitivity (Sn.) and
47 specificity (Sp.) reflect whether a given seroprevalence result is accurately reflective of the
48 sample group's true antibody positivity. Sn. and Sp. are not fixed properties of an assay - they
49 are dependent on the panel of samples they were tested with. Manufacturers, third-party sources,

50 and other independent groups conduct performance evaluations on the Sn. and Sp. of assays to
51 ensure the reliability and comparability of seroprevalence results. These evaluations use panels
52 with different compositions of samples, some of which are likely to produce high estimates.
53 Thus, the evaluation performance of assays varies considerably. Recently, a review compared
54 serological assay performance against RT-PCR results for 58 studies^[3]. The authors found that
55 among ELISAs, CLIAs, and LFIAs, the pooled assay Sn. and Sp. ranged from 75% - 91% (Sn.)
56 and 92% - 100% (Sp.). This broadly varying assay performance raises the concern that SARS-
57 CoV-2 seroprevalence estimates may be biased by imperfect or inconsistent assay performance,
58 especially in cases where no statistical adjustments are made to account for test performance.

59
60 Validation from different sources is often in disagreement and results in varied intra-assay
61 performance data especially compared to manufacturer-certified evaluations, as supported by
62 several head-to-head laboratory assay comparison studies^[4-8]. Commercial assays constitute the
63 vast majority of assays used in serosurveys, and manufacturers of these commercial assays self-
64 certify their testing products with in-lab evaluations^[9]. Such evaluations were usually done in the
65 early pandemic using small true positive samples drawn from patients with confirmed
66 symptomatic COVID-19 and no co-infection of other viruses^[10]. The lack of endemic samples
67 representing the demographics and endemic pathogens in a study area introduces spectrum
68 bias^[11]. There is also a lack of standardization between the methodology for manufacturer
69 evaluations, and key factors such as the time post-symptom onset that sampling was done vary.

70
71 There is uncertainty in the extent to which mis-specified assay performance will introduce bias to
72 results in unadjusted and adjusted seroprevalence estimates. This issue is further exacerbated by

73 the discordant validation data between sources and the unavailability of third-party evaluations
74 for certain assays. For this reason, there is a need to synthesize assay performance data for use in
75 both the design and interpretation of serosurveys, In particular, how these sources of validation
76 data differ and what the Sn. and Sp. of an assay are needed to minimize bias in seroprevalence
77 estimates given the true background prevalence. These results have important implications for
78 public health policy and resource mobilization through the interpretation of seroprevalence data:
79 especially critical for the future course of the pandemic and advising serosurveillance for future
80 infectious disease threats.

81
82 Our group maintains a living systematic review of SARS-CoV-2 seroprevalence^[12]. We sought
83 to 1) describe features and usage of serological assays, as well as the implementation of testing
84 algorithms employing multiple tests in SARS-CoV-2 serosurveys during the COVID-19
85 pandemic; 2) comprehensively compare the performance of these assays across manufacturers,
86 third-party reference labs, and independent investigator evaluations; and 3) quantitatively assess
87 the influence of assay performance on seroprevalence estimates. To our knowledge, this is the
88 first large-scale evaluation of discrepancies between validation sources and intra-assay
89 performance for serological assay targeting SARS-CoV-2 antibodies.

90

91 **Materials and Methods**

92 This study is registered as a part of an ongoing living systematic review of global SARS-CoV-2
93 seroprevalence studies in PROSPERO (CRD42020183634^[12]), which is also accessible on the
94 open-access web dashboard, SeroTracker^[13]. Detailed methods and results from this review have
95 previously been published^[14, 15].

96 *Data sources and search strategy*

97 We created a search strategy that was as thorough as possible in comprehending the
98 immunoassays utilized in seroprevalence studies. All identified articles were recorded in the
99 SeroTracker database, a database containing the most comprehensive source of seroprevalence
100 research ever made available. The search strategy identified published literature, and preprints
101 was created in collaboration with a health sciences librarian. We sought to reduce any potential
102 publishing bias by adding a range of sources besides peer-reviewed publications, including
103 institutional reports, media sources, and grey literature. Experts who collaborated with us and the
104 users of the SeroTracker website recommended grey literature.^[14] From the search dates of
105 January 1st, 2020, to November 19th, 2021, we searched for articles on Medline, EMBASE, and
106 Web of Science preprints on Europe PMC. Our secondary search included Google News, articles
107 submitted to SeroTracker.com, and studies submitted to us by expert recommendations. Two
108 reviewers independently screened titles/abstracts and full texts. Data were extracted and critically
109 appraised in duplicate^[16].

110
111 *Inclusion and exclusion criteria*

112 We included all SARS-CoV-2 seroprevalence studies in humans which reported a sample size,
113 sampling date and locale, and prevalence estimate. We excluded studies conducted only in
114 people with SARS-CoV-2 infection or vaccination and online public dashboard estimates that
115 were not associated with a defined serology study^[15]. We adapted an automated appraisal tool
116 based on the Joanna Briggs Institute critical checklist to evaluate the risk of bias in included
117 seroprevalence studies^[17]. Full details of the assessment process can be accessed from this
118 preprinted work^[16].

119

120 *Serological assay data extraction*

121 We extracted all data for serological assays to develop an independent database linked to the
122 master seroprevalence study database. It included assay-related information reported in
123 individual seroprevalence studies. For each assay, we identified product name, manufacturer or
124 developer, country, WHO geographical region of development, antibody isotypes detected (IgG,
125 IgM, IgA, total Ab), test type (ELISA, LFIA, IFA, CLIA, neutralization assay, others; see
126 Supplementary Files Table S1), antibody target (Spike, Nucleocapsid, others), multiplex
127 detection (detecting more than one antibody targets), time to result (Rapid Diagnostic Tests
128 [RDT]/non-RDT), and test Sn. and Sp. as reported by manufacturers or developers. For
129 commercial assays, we validated and complemented details on assays using reference links
130 provided by authors. These links directed us to manufacturer's websites or user's guides which
131 contained detailed information on the given assay. For self-developed assays, reference links
132 pointed to the original research article with comprehensive development details.

133
134 Many studies cited serological assay validation results to corroborate the performance of the
135 assay they selected. However, given that the testing environment, validation procedure, and
136 reference panel varied across groups conducting validation, we categorized assay validation as
137 either (1) third-party lab validation or (2) independent group field validation. We linked
138 commercial assays with their performance in five large third-party lab performance evaluations
139 and defined these as third-party lab validations. These five labs conducted large-scale head-to-
140 head evaluations under controlled and reproducible conditions, including NRL (WHO
141 sponsored^[4]), the US FDA^[5], Netherland CIDC^[6], The Doherty Institute^[7], and FIND
142 Diagnostics^[8](Table S2). Independent field validation^[8] results were defined as performance
143 validation data extracted from individual seroprevalence studies. These studies reported pretest

144 results with a smaller sample in addition to population prevalence. Where available, assays' Sn.
145 and Sp. for all isotypes and total antibodies were extracted from third-party lab evaluations and
146 independent evaluations. The WHO has set performance criteria for the emergency use of Sn. \geq
147 90.0% and Sp. \geq 97.0%^[18]. We applied these thresholds to categorize commercial assays based
148 on performance in manufacturer, third-party, and independent evaluations.

149
150 Evaluation data was not very available for self-developed assays as for commercial assays, in the
151 assay description of which concentrated on the steps of developing such an assay with
152 performance matrices provided randomly. Therefore, corresponding performance analysis was
153 not conducted for self-developed assays.

154 155 Analysis

156 Data extraction, cleaning, and management were performed in a collaborative data collection
157 platform (Airtable.com). Data analysis was performed using R 4.0.2^[19]. We first summarized
158 basic study characteristics, seroprevalence estimates, and serological assay features stratified by
159 the WHO region at the study level.

160
161 At the assay level, we described the distribution of test usage, initial adoption, test type, region of
162 development, test features, test evaluation states, and eligibility for emergency use by
163 commercial and self-developed assays. We collected Sn./Sp. data to show the difference in
164 reported performance for the top 50 assays and the top 20 assays by evaluation sources
165 (manufacturers, third parties, and independent groups). The median Sn. and Sp. values for the
166 top 50 assays were extracted from three evaluation sources and plotted on a panel against the

167 WHO criteria. Bland-Altman plots were created to compare manufacturer-reported Sn./Sp. with
168 a third party's lab and independently evaluated Sn./Sp. in pairs.

169

170 For studies that used a testing algorithm involving multiple assays, we examined the combination
171 of assays used (commercial/self-developed), how results from assays were combined (e.g., either
172 test positive for a specimen to be positive vs. both tests positive), and whether the study reported
173 a combined Sn. and Sp. for the testing algorithm. Many studies used multiple assay testing
174 algorithms and also reported seroprevalence derived from using individual assays on the same
175 set of samples. For these studies, we generated another set of Bland-Altman plots to show the
176 discrepancy of estimates between testing algorithms. Seroprevalence estimates given by multiple
177 assay algorithms and seroprevalence given by individual assays were compared in pairs.

178

179 Modeling analysis

180 In examining whether assay performance differs by evaluation sources, we developed separate
181 mixed-effect beta regression models for Sn. and Sp. with random effects specified for individual
182 serological assays. Given that data with high heterogeneity, a diagonal heterogeneous variance-
183 covariance structure was finally selected when estimating the assay performance by evaluation
184 source. Assay features of isotype, test type, antibody targets, multiplex detection, and time to
185 result were fitted as covariates to adjust outputs. Raw log odds obtained from models were
186 converted to percentage for ease of interpretation. Difference in performance matrix against
187 manufacturer values with 95% Confidence Interval (95% CI) by evaluation sources was derived
188 using bootstrapping with 10000 iterations. This modeling analysis enables us to determine

189 discordance between evaluation sources and how inherent assay features may affect performance
190 metrics.

191
192 We then performed a simulation. We simulated 1000 scenarios in which observed
193 seroprevalence ranged from 0.0-99.9%. We adjusted assay performance^[20] on observed
194 prevalence to answer the third question we asked – to what extent a misreported assay
195 performance value will bias the adjusted estimates from the ‘true’ prevalence estimate. The
196 precise prevalence estimate intervals were defined by specifying error levels at $\pm 5\%$ ^[21] to the
197 true prevalence. We simulated adjusted seroprevalence for assays at three accuracy levels – 1)
198 high: Sn. = 95.0%, Sp. = 99.0%; 2) good: Sn. = 90.0%, Sp. = 97.0%; 3) moderate: Sn. = 87.0%,
199 Sp. = 90.0%, with different levels of error of performance misspecification.

200

201 **Results**

202 Included studies

203 We screened 72,799 titles and abstracts and 4,876 full texts published between January 1, 2020,
204 and November 19, 2021. This represents the pre-booster vaccine time window before Omicron
205 where most qualitative tests were introduced. We extracted data from 2,069 articles – 262 of
206 these were identified as preprints, overlapped by subsequent full articles. 1,807 serosurveys were
207 included for final analysis (see Supplemental Files Figure S1).

208

209 Assay use in seroprevalence studies

210 Among these 1,807 serosurveys, 80.7% of studies used a single serological assay (73.1%
211 commercial assays, 18.2% self-developed assays, 8.7% unable to specify), while 19.3% used a
212 testing algorithm involving multiple assays (Table S3 and S5); 248 adjusted seroprevalence

213 estimates for assay performance. Overall, global usage of commercial serology assays follows a
214 power-law distribution, with the top 25 assays accounting for 67.0% of total commercial assay
215 use in seroprevalence studies (Figure S2) and the top 50 assays accounting for 91.4% of use.

216
217 *Characteristics of identified assays*

218 Among 1807 serosurveys, we identified 192 commercial serology assays and 380 self-developed
219 serology assays (Table 1). A full list of identified commercial serology assays can be found in
220 Supplemental Files (Table S6). Of the 192 identified commercial assays, 31.3% were ELISAs,
221 39.1% were LFIAs, 15.6% were CLIAs, 2.6% were IFA assays, and 15.6% were other types or
222 not able to specify (Table 1). Of the 380 studies using self-developed assays, most used ELISAs
223 (68.7%, Table 1). Product information was limited for many assays, most notably LFIAs: up to
224 32.6% and 42.6% of studies did not mention details about targeted antigen(s) and antibody
225 isotypes, respectively. 45.0% of studies using self-developed assays used multiplex detection to
226 recognize multiple antibody targets. RDTs (types including LFIA, and IFA) accounted for 53.6%
227 (103/192) of all commercial assays, while only 4.5% (17/192) of self-developed assays were
228 developed as RDTs.

229
230 *Reporting of assay performance*

231 Manufacturer data could be searched from publicly available online sources or manufacturer-led
232 research papers for 91/192 (47.4%) commercial assays; 61.5% of these were subsequently either
233 assessed in the five third-party evaluations or independent group evaluations (Table 2). Based on
234 manufacturer data, the mean Sn. was 97.8 (95% CI: 93.9-100) % and the mean Sp. was 99.7
235 (95% CI: 97.8-100)%; 55/192 (28.6%) met the 90.0% Sn. and 97.0% Sp. WHO criteria for
236 emergency use (Figure 1, Figure 2); of the 50 most frequently used assays, 76.9% met the WHO

237 criteria. In contrast, only 46.1% and 53.7% met these criteria based on third-party and
238 independent evaluations, respectively (Figure 2).
239
240 CLIAs demonstrated higher and more reliable performance across all three evaluation sources
241 than ELISAs, LFIAs, and IFAs among the top 50 assays (Figure 1, Figure S3). The pairing
242 comparison of manufacturer-reported figures of merit against five third-party lab and
243 independent group evaluations indicated manufacturers systematically overstated the Sn. and Sp.
244 of the assays they developed (Figure S4, Figure S5). After adjusting for assay features, Sn. and
245 Sp. were considerably lower by 1.0% (95% CI: 0.1-1.4)% ($p=0.289$) and 0.9% (95% CI: 0.9-
246 0.9)% ($p<0.001$) according to third parties and by 3.3 (95% CI: 2.7-3.4)% ($p=0.001$) and 0.2
247 (95% CI: -0.1, 0.4)% ($p=0.247$, Table 2) according to independent evaluations.

248
249 We conducted a simulation to examine the impact of incorrect Sn. and Sp. estimates on
250 estimated seroprevalence, using a threshold of $\pm 5\%$ between true and adjusted prevalence to
251 define substantial effects. Falsely specifying Sn. 5% higher than its true value will not affect
252 population prevalence estimates for any assay with higher than moderate performance (Sn. \geq
253 80%, Sp. \geq 87%). However, if Sn. is falsely specified by 10% higher and Sp. by 3% higher,
254 population prevalence estimates are inaccurate for true prevalence below 18.3% or above 38.7%
255 (assays with moderate performance), or inaccurate for true prevalence below 17.5% or above
256 41.5% (assays with good performance, i.e., Sn = 90%, Sp = 97%). Falsely specifying assay Sn.
257 10% lower and Sp. 5% lower than their true values lead to substantial deviations between
258 estimated and true population seroprevalence at all seroprevalence values(Figure 3. a-c, Table
259 S4).

260

261 *Multiple test combinations*

262 349/1807 (19.3%) studies employed a testing algorithm that used more than one serological
263 assay (Table S5). Most studies (254/349 [72.8%]) used a combination of the commercial test(s)
264 with self-developed test(s) and employed multiple laboratory-based (i.e., non-RDT) assays
265 (267/349 [76.5%]). Concerning antibody targets, 152 (43.5%) studies combined spike and
266 nucleocapsid-targeted assays, while spike-spike assay combinations were observed in 121/349
267 (34.7%) studies.

268

269 Of 349 multiple-testing studies, 42.4% of these tested the same sample on multiple assays
270 concurrently (“parallel testing”); among these, 68.2% defined seropositivity as a positive result
271 on at least one assay, and 31.8% defined this as a positive result on all assays. 31.8% used one
272 assay first for screening, followed by another for confirmation (“sequential testing”). While
273 having the combined Sn. and Sp. for a testing algorithm is important to interpret seroprevalence
274 estimates, this was only reported in 9.5% of seroprevalence studies using multiple testing
275 algorithms (Table S5). A subset of samples from 167 studies tested on parallel or sequential
276 multiple algorithms were identified to interpret seroprevalence estimates derived from these
277 algorithms. These studies also have estimates provided by a single assay. We found parallel and
278 sequential testing algorithms were potentially effective in ruling out false-positive cases given by
279 RDTs (-7.8% in prevalence estimates using a single assay) and recognizing positive cases missed
280 by ELISAs (+4.4%, Figure S6).

281

282 **Discussion**

283 In examining 1807 global serosurveys published between January 1st, 2020, and November 19th,
284 2021, we found that 192 unique commercial and 380 unique self-developed serological assays
285 were used. 50 commercial assays are used across 91% of SARS-CoV-2 seroprevalence studies.
286 We found that intra-assay performance evaluations varied widely according to evaluation
287 method and source. This variation in assay evaluations may have an impact on seroprevalence
288 estimate validity and bias by under- or over-estimating estimates by up to 9.5%.

289

290 Serological assay performance is context dependent. Previous literature did not focus on
291 assessing intra-assay consistency across different sources of validation for assays but put more
292 emphasis on inter-assay comparisons^[22–26]. Our study reveals that manufacturer evaluations of
293 assay Sn. and Sp. were overestimations compared to independent and third-party head-to-head
294 validations. Our pooled analysis found that Sn. on average was lower by 1.0% and 3.3% in third
295 party's and independent group evaluations, respectively. Likewise, Sp. on average was lower by
296 0.9% and 0.2% in third party's and independent group evaluations, respectively. These results
297 imply there may be more false positives and negatives than would be expected given
298 manufacturer-verified test evaluations, which may impact result adjustment and interpretation.

299

300 *Third-party evaluation validates manufacturer data*

301 Third-party evaluations are essential for more objective estimates of Sn. and Sp., enabling
302 retrospective adjustment of seroprevalence data and selecting candidate assays for new studies.
303 The five third-party labs included in our study all disclosed the reference panel they used (Table
304 S2). The composition of samples in reference panels is consistent across the evaluation of each
305 individual assay, including testing materials consisting of combinations of high-titer, mid-titer,

306 and low-titer samples on N- and S- antibody targets. Reference panels reflect the full-time course
307 of infection (past infections, and waning antibodies). It also mirrors the complexity of antibody
308 detection in real settings^[27, 28], as cross-reactivity to other viral infections (such as HIV, Dengue,
309 Malaria, and Middle East Respiratory Syndrome) was also consistently assessed in negative
310 panels. Third-party evaluations are of value in retrospectively adjusting data or selecting and
311 adjusting for assays in new studies. However, these evaluations typically only target frequently
312 used commercial ELISA and CLIA assays, which were less distributed in low-income regions
313 like Africa (Table S3).

314

315 *Independent evaluation reflects regional population characteristics*

316 This situation necessitates that study investigators validate assays not included in these third-
317 party evaluations. These independent evaluations better reflect the study geography,
318 demographic context, epidemiological time course, and variant landscape, minimizing
319 spectrum bias. Of note, studies have demonstrated loss of Sn. over time as antibodies wane, and
320 incorporating performance based on time since the infection will gain further importance as the
321 pandemic progresses^[10, 29]. Moreover, viral mutations may result in decreased assay performance
322 ^[30]. Additionally, studies have shown differences in antibody dynamics in specific populations
323 such as those from sub-Saharan Africa, young adults, and pregnant women that may impact test
324 performance^[31–34]. This step is not always feasible for all research settings, as we found only a
325 small proportion (6.9%) of independent author groups conducted their own assay pre-study
326 validation before rolling out their serosurvey. Fewer described the evaluation panels and
327 methods they used. We encourage future studies to integrate assay evaluation more into a
328 serosurvey design as a pre-step. Independent evaluations targeted toward the intended study

329 population will update the understanding of serological assay performance, and conversely,
330 accurate seroprevalence estimates.

331

332 Correct seroprevalence estimate for assay performance

333 Seroprevalence estimates can vary considerably based on the assay used, even in the same
334 population and based on the same samples^[23]. For instance, low-Sp. assays can lead to
335 overinflated seroprevalence estimates, creating misleading results — particularly in settings with
336 low true prevalence^[35]. Moreover, Sn. and Sp. are not true parameters of the assays, but can vary
337 for the same assay depending on the reference panel or population used. Overall, our findings
338 caution against accepting aggregate Sn. and Sp. reported by assay manufacturers, favoring
339 independent or third-party evaluations on representative populations. Sn. and Sp. should be
340 stratified by disease severity and time since infection, and the characteristics of the positive and
341 negative reference panels should be reported at a minimum . The chance of biased estimates can
342 be substantially minimized with proper adjustment. Our finding implies that statistically
343 adjusting for test validity may be an essential step - particularly in low prevalence settings where
344 a small absolute difference in seroprevalence can produce a massive relative difference in
345 understanding of case ascertainment, and/or where assay performance values are low (as seen
346 with some rapid test assays).

347

348 Multiple testing

349 Another option to minimize bias in seroprevalence studies was to use a multiple-testing strategy.
350 Although findings should be further validated due to the heterogeneity of data, we noticed that
351 pairing RDT with other assays could minimize false-positive rates by using RDTs only. RDT as
352 a preliminary screening test suggests whether the test recipient produces any antibodies against

353 SARS-CoV-2 in general. The series of confirmation tests identifies the source of antibodies
354 (infection/ vaccination) and helps determine a more precise timepoint of infection^[36]. Moreover,
355 multiple testing algorithms could also increase the Sn. of laboratory binding assays such as
356 ELISAs and CLIAs and rule out false negatives, especially in low prevalence settings. Requiring
357 a positive result on multiple assays in parallel and sequential testings improves the overall Sp. of
358 the testing algorithm compared with the individual assays alone^[37], but sometimes at the expense
359 of Sn.^[38]; conversely, requiring a positive result on just one of multiple assays improves Sn. at
360 the expense of Sp. Sn. and Sp. should be taken as a whole to improve the positive predicted
361 value of a testing algorithm to truly identify positive cases among all positive tests. Rational
362 deployment of these algorithms should also consider contextual factors such as background
363 prevalence in the population being studied, as positive predictive values are substantially lower
364 in low prevalence settings^[27]. Additionally, for accurate interpretation, reporting the details of
365 the assays used and how they were combined with one another is important. The combined Sn.
366 and Sp. is calculatable for multiple testing algorithms based on individual performance features
367 under either rule^[36, 39], but reporting a combined Sn. and Sp. at the point of completing all steps
368 for a multiple testing algorithm on a regional sample is more preferable.

369

370 Limitations

371 This study has some limitations. While the living review from which our data is drawn captures
372 all seroprevalence studies, we have not captured all applications of serological assays. For
373 example, we excluded studies done exclusively in confirmed COVID-19 cases and vaccinated
374 individuals, and our findings may not apply to these areas of serological research. Additionally,
375 our findings apply to population-based contexts and may not translate to the patient or clinical

376 level, where serological assays are used to guide patient care. When collating third-party,
377 independent, and manufacturer data on assay performance, we extracted the overall Sn./Sp. on
378 total antibodies whenever available. We performed an empirical synthesis, making the best effort
379 to collate all assay performance data accessible from online dashboards, preprints, institutional
380 reports, and academic journals by identified sources. We extracted performance data collected
381 from the far-most day from symptom onset. Finally, while we made our best effort to identify
382 and summarize the use of serological assays in each serosurvey and the performance of assays
383 from different sources, we saw people miss reporting performance matrices for self-developed
384 assays. Therefore, we did not proceed with analyses for self-developed assays on performance
385 comparison. Studies released as conference abstracts (48/1807, 2.7%) did not have enough space
386 to describe the type of test used in a serosurvey in detail. But given that the number of
387 conference abstracts is small, it did not contribute a major result bias.

388

389 **Conclusions**

390 In conclusion, we found a large and diverse number of assays used in seroprevalence studies.
391 This diverse selection of serological assays may impact the interpretation and reliability of
392 seroprevalence estimates by up to $\pm 9.5\%$, as Sn. and Sp. are not fixed properties of a serological
393 assay but varying features depending on the reference panel or population on which is tested. We
394 strongly recommend that: 1) authors conducting seroprevalence studies should consider adopting
395 third-party or independently evaluated assays, which inform assay properties in a particular
396 context; 2) statistical test adjustments on population seroprevalence should be employed using
397 validated assay performance data; and 3) utilizing multiple testing strategies where possible

398 (reporting a combined overall Sn. and Sp.) to minimize the risk of bias in seroprevalence

399 estimates.

400

401 **Transparency declaration**

402 **Supplementary Materials:** Supplementary file 1 contains an article inclusion diagram, an
403 explanation of major categories of assays, a description of reference panels of five third-party lab
404 evaluations, supplementary analytical results, and the full list of identified commercial serology
405 assays from the systematic review. Supplementary file 2 is the PRISMA checklist required for a
406 review article.

407 **Funding:** SeroTracker receives funding for SARS-CoV-2 seroprevalence study evidence
408 synthesis from the Public Health Agency of Canada through Canada’s COVID-19 Immunity
409 Task Force, the World Health Organization Health Emergencies Programme, the Robert Koch
410 Institute, and the Canadian Medical Association Joule Innovation Fund.
411 L.S. is employed by WHO; no others at WHO, and no other funders, had any role in the design
412 of this study, its execution, analyses, interpretation of the data, or decision to submit results. This
413 manuscript does not necessarily reflect the views of the World Health Organization or any other
414 funder.

415 **Acknowledgments:** We would like to thank all members of the SeroTracker team who built the
416 foundation for this study by maintaining an up-to-date database of seroprevalence studies.

417 **Author Contributions:** Conceptualization, X.M., Z.L., N.B. and R.K.A.; Methodology, X.M.,
418 Z.L., L.S., N.B., and R.K.A.; Software, X.M., Z.L., and C.C.; Validation, Z.L., M.W., D.K.,
419 C.C., M.Y.L, and T.Y.; Formal Analysis, X.M.; Investigation, X.M., and Z.L.; Resources,
420 R.K.A., N.B., T.J., M.C., D.A.C., and L.S.; Data Curation, X.M., Z.L., and C.C.; Writing –
421 Original Draft Preparation, X.M., Z.L., D.K., and R.K.A.; Writing – Review & Editing,
422 Everyone on the author list; Visualization, X.M., and R.K.A.; Supervision, R.K.A; Project
423 Administration, X.M.; Funding Acquisition, R.K.A, N.B., and T.Y.

424 **Institutional Review Board Statement:** Ethical review and approval were waived for this
425 study, due to only second-hand synthesized data were used.

426 **Informed Consent Statement:** Not applicable.

427 **Data Availability Statement:** Data from seroprevalence studies and the serological assays used
428 therein are available from: <https://serotracker.com/en/Explore>

429 **Conflict of interest:** R.K.A. reports consulting fees from the Bill and Melinda Gates Foundation
430 Strategic Investment Fund, past employment with Health Canada, and equity in Alethea Medical,
431 all outside the submitted work. D.A.C. reports consulting fees from Sensyne Health, Oxford
432 University Innovation, and BioBeats, each outside the submitted work.

433

434 References

- 435 [1] Peeling, R. W.; Wedderburn, C. J.; Garcia, P. J.; Boeras, D.; Fongwen, N.; Nkengasong, J.;
436 Sall, A.; Tanuri, A.; Heymann, D. L. Serology Testing in the COVID-19 Pandemic
437 Response. *Lancet Infect. Dis.*, **2020**, *20* (9), e245–e249. [https://doi.org/10.1016/S1473-](https://doi.org/10.1016/S1473-3099(20)30517-X)
438 [3099\(20\)30517-X](https://doi.org/10.1016/S1473-3099(20)30517-X).
- 439 [2] Ghaffari, A.; Meurant, R.; Ardakani, A. COVID-19 Serological Tests: How Well Do They
440 Actually Perform? *Diagn. Basel Switz.*, **2020**, *10* (7), E453.
441 <https://doi.org/10.3390/diagnostics10070453>.
- 442 [3] Makoah, N. A.; Tipih, T.; Litabe, M. M.; Brink, M.; Sempa, J. B.; Goedhals, D.; Burt, F. J.
443 A Systematic Review and Meta-Analysis of the Sensitivity of Antibody Tests for the
444 Laboratory Confirmation of COVID-19. *Future Virol.*, **2021**. [https://doi.org/10.2217/fvl-](https://doi.org/10.2217/fvl-2021-0211)
445 [2021-0211](https://doi.org/10.2217/fvl-2021-0211).
- 446 [4] NRL Science of Quality. *WHO SARS-CoV-2 Test Kit Comparative Study*.
- 447 [5] U.S. Food and Drug Administration. *Independent Evaluations of COVID-19 Serological*
448 *Tests*.
- 449 [6] van den Beld, M. J. C.; Murk, J.-L.; Kluytmans, J.; Koopmans, M. P. G.; Reimerink, J.; van
450 Loo, I. H. M.; Wegdam-Blans, M. C. A.; Zaaijer, H.; Serology Workgroup for SARS-CoV-
451 2; GeurtsvanKessel, C.; et al. Increasing the Efficiency of a National Laboratory Response
452 to COVID-19: A Nationwide Multicenter Evaluation of 47 Commercial SARS-CoV-2
453 Immunoassays by 41 Laboratories. *J. Clin. Microbiol.*, **2021**, *59* (9), e0076721.
454 <https://doi.org/10.1128/JCM.00767-21>.
- 455 [7] Australian Government Department of Health Therapeutic Goods Administration. *Post-*
456 *Market Evaluation of Serology-Based Point of Care Tests*.
- 457 [8] FIND Diagnostics for All. *SARS-CoV-2 Test Performance*.
- 458 [9] Department of Health and Social Care (DHSC). *Validating COVID-19 Tests in the Private*
459 *Market*.
- 460 [10] Peluso, M. J.; Takahashi, S.; Hakim, J.; Kelly, J. D.; Torres, L.; Iyer, N. S.; Turcios, K.;
461 Janson, O.; Munter, S. E.; Thanh, C.; et al. SARS-CoV-2 Antibody Magnitude and
462 Detectability Are Driven by Disease Severity, Timing, and Assay. *Sci. Adv.*, **2021**, *7* (31),
463 eabh3409. <https://doi.org/10.1126/sciadv.abh3409>.
- 464 [11] Einhauser, S.; Peterhoff, D.; Niller, H. H.; Beileke, S.; Günther, F.; Steininger, P.;
465 Burkhardt, R.; Heid, I. M.; Pfahlberg, A. B.; Überla, K.; et al. Spectrum Bias and Individual
466 Strengths of SARS-CoV-2 Serological Tests—A Population-Based Evaluation.
467 *Diagnostics*, **2021**, *11* (10), 1843. <https://doi.org/10.3390/diagnostics11101843>.
- 468 [12] Bobrovitz, N. *A Systematic Review and Meta-Analysis of SARS-CoV-2 Seroprevalence*
469 *Studies Aligned with the WHO Population-Based Sero-Epidemiological ‘Unity’ Protocol;*
470 *PROSPERO 2020 CRD42020183634; PROSPERO International prospective register of*
471 *systematic reviews*.
- 472 [13] Arora, R. K.; Joseph, A.; Van Wyk, J.; Rocco, S.; Atmaja, A.; May, E.; Yan, T.; Bobrovitz,
473 N.; Chevrier, J.; Cheng, M. P.; et al. SeroTracker: A Global SARS-CoV-2 Seroprevalence
474 Dashboard. *Lancet Infect. Dis.*, **2021**, *21* (4), e75–e76. [https://doi.org/10.1016/S1473-](https://doi.org/10.1016/S1473-3099(20)30631-9)
475 [3099\(20\)30631-9](https://doi.org/10.1016/S1473-3099(20)30631-9).
- 476 [14] Bobrovitz, N.; Arora, R. K.; Cao, C.; Boucher, E.; Liu, M.; Donnici, C.; Yanes-Lane, M.;
477 Whelan, M.; Perlman-Arrow, S.; Chen, J.; et al. Global Seroprevalence of SARS-CoV-2

- 478 Antibodies: A Systematic Review and Meta-Analysis. *PloS One*, **2021**, *16* (6), e0252617.
479 <https://doi.org/10.1371/journal.pone.0252617>.
- 480 [15] Bergeri, I.; Whelan, M.; Ware, H.; Subissi, L.; Nardone, A.; Lewis, H. C.; Li, Z.; Ma, X.;
481 Valenciano, M.; Cheng, B.; et al. Global Epidemiology of SARS-CoV-2 Infection: A
482 Systematic Review and Meta-Analysis of Standardized Population-Based Seroprevalence
483 Studies, Jan 2020-Dec 2021. *medRxiv*, **2022**, 2021.12.14.21267791.
484 <https://doi.org/10.1101/2021.12.14.21267791>.
- 485 [16] Bobrovitz, N.; Noel, K. C.; Li, Z.; Cao, C.; Deveaux, G.; Selemon, A.; Clifton, D. A.;
486 Yanes Lane, M.; Yan, T.; Arora, R. K. *SeroTracker-RoB: An Approach to Automating*
487 *Reproducible Risk of Bias Assessment of Seroprevalence Studies*; preprint; *Epidemiology*,
488 2021. <https://doi.org/10.1101/2021.11.17.21266471>.
- 489 [17] The Joanna Briggs Institute. *Critical Appraisal Tools for Use in JBI Systematic Reviews*
490 *Checklist for Prevalence Studies*.
- 491 [18] World Health Organization. *Target Product Profiles for Priority Diagnostics to Support*
492 *Response to the COVID-19 Pandemic v.1.0*.
- 493 [19] R Core Team, R. C. T. R: A Language and Environment for Statistical Computing.
- 494 [20] Sempos, C. T.; Tian, L. Adjusting Coronavirus Prevalence Estimates for Laboratory Test
495 Kit Error. *Am. J. Epidemiol.*, **2021**, *190* (1), 109–115. <https://doi.org/10.1093/aje/kwaa174>.
- 496 [21] Pourhoseingholi, M. A.; Vahedi, M.; Rahimzadeh, M. Sample Size Calculation in Medical
497 Studies. *Gastroenterol. Hepatol. Bed Bench*, **2013**, *6* (1), 14–17.
- 498 [22] Caini, S.; Bellerba, F.; Corso, F.; Díaz-Basabe, A.; Natoli, G.; Paget, J.; Facciotti, F.; De
499 Angelis, S. P.; Raimondi, S.; Palli, D.; et al. Meta-Analysis of Diagnostic Performance of
500 Serological Tests for SARS-CoV-2 Antibodies up to 25 April 2020 and Public Health
501 Implications. *Euro Surveill. Bull. Eur. Sur Mal. Transm. Eur. Commun. Dis. Bull.*, **2020**, *25*
502 (23). <https://doi.org/10.2807/1560-7917.ES.2020.25.23.2000980>.
- 503 [23] Lisboa Bastos, M.; Tavaziva, G.; Abidi, S. K.; Campbell, J. R.; Haraoui, L.-P.; Johnston, J.
504 C.; Lan, Z.; Law, S.; MacLean, E.; Trajman, A.; et al. Diagnostic Accuracy of Serological
505 Tests for Covid-19: Systematic Review and Meta-Analysis. *BMJ*, **2020**, *370*, m2516.
506 <https://doi.org/10.1136/bmj.m2516>.
- 507 [24] Whitman, J. D.; Hiatt, J.; Mowery, C. T.; Shy, B. R.; Yu, R.; Yamamoto, T. N.; Rathore,
508 U.; Goldgof, G. M.; Whitty, C.; Woo, J. M.; et al. Evaluation of SARS-CoV-2 Serology
509 Assays Reveals a Range of Test Performance. *Nat. Biotechnol.*, **2020**, *38* (10), 1174–1183.
510 <https://doi.org/10.1038/s41587-020-0659-0>.
- 511 [25] Vengesai, A.; Midzi, H.; Kasambala, M.; Mutandadzi, H.; Mduluza-Jokonya, T. L.;
512 Rusakaniko, S.; Mutapi, F.; Naicker, T.; Mduluza, T. A Systematic and Meta-Analysis
513 Review on the Diagnostic Accuracy of Antibodies in the Serological Diagnosis of COVID-
514 19. *Syst. Rev.*, **2021**, *10* (1), 155. <https://doi.org/10.1186/s13643-021-01689-3>.
- 515 [26] Theel, E. S. Performance Characteristics of High-Throughput Serologic Assays for Severe
516 Acute Respiratory Syndrome Coronavirus 2 with Food and Drug Administration
517 Emergency Use Authorization: A Review. *Clin. Lab. Med.*, **2022**, *42* (1), 15–29.
518 <https://doi.org/10.1016/j.cll.2021.10.006>.
- 519 [27] U.S. Food & Drug Administration. *EUA Authorized Serology Test Performance*.
- 520 [28] Stein, D. R.; Osiowy, C.; Gretchen, A.; Thorlacius, L.; Fudge, D.; Lang, A.; Sekirov, I.;
521 Morshed, M.; Levett, P. N.; Tran, V.; et al. Evaluation of Commercial SARS-CoV-2
522 Serological Assays in Canadian Public Health Laboratories. *Diagn. Microbiol. Infect. Dis.*,
523 **2021**, *101* (3), 115412. <https://doi.org/10.1016/j.diagmicrobio.2021.115412>.

- 524 [29] Takahashi, S.; Greenhouse, B.; Rodríguez-Barraquer, I. Are Seroprevalence Estimates for
525 Severe Acute Respiratory Syndrome Coronavirus 2 Biased? *J. Infect. Dis.*, **2020**, 222 (11),
526 1772–1775. <https://doi.org/10.1093/infdis/jiaa523>.
- 527 [30] Lippi, G.; Adeli, K.; Plebani, M. Commercial Immunoassays for Detection of Anti-SARS-
528 CoV-2 Spike and RBD Antibodies: Urgent Call for Validation against New and Highly
529 Mutated Variants. *Clin. Chem. Lab. Med.*, **2021**. <https://doi.org/10.1515/cclm-2021-1287>.
- 530 [31] Tso, F. Y.; Lidenge, S. J.; Peña, P. B.; Clegg, A. A.; Ngowi, J. R.; Mwaiselage, J.;
531 Ngalamika, O.; Julius, P.; West, J. T.; Wood, C. High Prevalence of Pre-Existing
532 Serological Cross-Reactivity against Severe Acute Respiratory Syndrome Coronavirus-2
533 (SARS-CoV-2) in Sub-Saharan Africa. *Int. J. Infect. Dis. IJID Off. Publ. Int. Soc. Infect.*
534 *Dis.*, **2021**, 102, 577–583. <https://doi.org/10.1016/j.ijid.2020.10.104>.
- 535 [32] Emmerich, P.; Murawski, C.; Ehmen, C.; von Possel, R.; Pekarek, N.; Oestereich, L.;
536 Duraffour, S.; Pahlmann, M.; Struck, N.; Eibach, D.; et al. Limited Specificity of
537 Commercially Available SARS-CoV-2 IgG ELISAs in Serum Samples of African Origin.
538 *Trop. Med. Int. Health TM IH*, **2021**, 26 (6), 621–631. <https://doi.org/10.1111/tmi.13569>.
- 539 [33] Bottomley, C.; Otiende, M.; Uyoga, S.; Gallagher, K.; Kagucia, E. W.; Etyang, A. O.;
540 Mugo, D.; Gitonga, J.; Karanja, H.; Nyagwange, J.; et al. Quantifying Previous SARS-
541 CoV-2 Infection through Mixture Modelling of Antibody Levels. *Nat. Commun.*, **2021**, 12
542 (1), 6196. <https://doi.org/10.1038/s41467-021-26452-z>.
- 543 [34] Irwin, N.; Murray, L.; Ozynski, B.; Richards, G. A.; Paget, G.; Venturas, J.; Kalla, I.;
544 Diana, N.; Mahomed, A.; Zamparini, J. Age Significantly Influences the Sensitivity of
545 SARS-CoV-2 Rapid Antibody Assays. *Int. J. Infect. Dis. IJID Off. Publ. Int. Soc. Infect.*
546 *Dis.*, **2021**, 109, 304–309. <https://doi.org/10.1016/j.ijid.2021.07.027>.
- 547 [35] Vogel, G.; Couzin-Frankel, J. Grade: Incomplete. *Science*, **2020**, 370 (6520), 1023–1027.
548 <https://doi.org/10.1126/science.370.6520.1023>.
- 549 [36] Mead, R. Statistical Games 2 - Medical Diagnosis. *Teach. Stat.*, **1992**, 14 (3), 12–16.
550 <https://doi.org/10.1111/j.1467-9639.1992.tb00232.x>.
- 551 [37] Veyrenche, N.; Bolloré, K.; Pisoni, A.; Bedin, A.; Mondain, A.; Ducos, J.; Segondy, M.;
552 Montes, B.; Pastor, P.; Morquin, D.; et al. Diagnosis Value of SARS-CoV-2
553 Antigen/Antibody Combined Testing Using Rapid Diagnostic Tests at Hospital Admission.
554 *J. Med. Virol.*, **2021**, 93 (5), 3069–3076. <https://doi.org/10.1002/jmv.26855>.
- 555 [38] Luijkx, T.; Morgan, M. Sensitivity and Specificity of Multiple Tests. In *Radiopaedia.org*;
556 Radiopaedia.org, 2015. <https://doi.org/10.53347/rID-34868>.
- 557 [39] Weinstein, S.; Obuchowski, N. A.; Lieber, M. L. Clinical Evaluation of Diagnostic Tests.
558 *Am. J. Roentgenol.*, **2005**, 184 (1), 14–19. <https://doi.org/10.2214/ajr.184.1.01840014>.
559

560 **Figures and tables**

561

562 Figure 1. The difference in reported assay performance among manufacturer evaluation, third
563 party evaluation, and independent evaluation

564

565 *Note. The figure shows the side-by-side comparison of assay performance for the top 20 assays.*
566 *Performance evaluations came from three sources: manufacturer reports, third-party labs, and*
567 *independent groups. Intervals show the range of performance values for a certain assay derived*
568 *from the given evaluation source.*

569

570 Figure 2. Sensitivity and specificity based on a) Manufacturer, b) third-party, and c) independent
571 group evaluations for the top 50 most frequently used commercial serological assays

572

573

574 *Note: Both axes are on a log scale. Assays missing the corresponding source of evaluation were*
575 *not involved in the analysis. The vertical and the horizontal lines indicate the WHO thresholds*
576 *for Emergency Use Authorizations for COVID-19 serological assays: sensitivity minimum of*
577 *90.0%, and specificity minimum of 97.0%, respectively. Assays on the upper right area of each*
578 *panel meet the WHO criteria for emergency use based on the dataset in question.*

579

580 Figure 3. Consequences of correcting seroprevalence estimates using biased estimates of
581 sensitivity (Sn.) and specificity (Sp.): simulation-based analysis. Serological assay with a) high:

582 a true Sn. at 95.0% and a true Sp. at 99.0%, b) good: a true Sn. at 90.0% and a true Sp. at 97.0%,
583 c) and moderate performance: a true Sn. at 80.0% and a true Sp. at 87.0%.

584

585 *Note. * The dot-dash lines provide an interval which indicates the seroprevalence adjusted for*
586 *the misspecified assay performance at a given error level was still within $\pm 5\%$ deviation of the*
587 *true seroprevalence. The prevalence adjustment was performed using the formula by Sempos*
588 *and Tian^[20].*

589 *** Notice that an assay with underestimated Sn. and Sp. is unable to provide prevalence*
590 *estimates after adjustment at a low prevalence setting: a): 5.3% and b): 5.6%. An assay with*
591 *overestimated Sn. and Sp. tends to inflate seroprevalence after adjustment when the true*
592 *prevalence is low: b) 3.0% and c) 9.6%.*

Table 1. Features of commercial and self-developed serology assays used by studies

Assay characteristics	Commercially assays (N = 192)		Self-developed assays (N = 380)	
	n	%	n	%
Developed by				
<i>Manufacturer</i>	162		-	
<i>Lab groups</i>	-		275	
Type of Assays				
<i>ELISA</i>	60	31.3	261	68.7
<i>LFIA</i>	75	39.1	0	0.0
<i>IFA</i>	5	2.6	17	4.5
<i>CLIA (Including CGIA, CMIA)</i>	30	15.6	3	0.8
<i>Neutralization Assay</i>	0	0.0	52	13.7
<i>Others/ Not specified</i>	22	11.5	47	12.4
WHO regions of development				
<i>Africa</i>	0	0.0	12	3.2
<i>America</i>	49	25.5	152	40.0
<i>Eastern Mediterranean</i>	5	2.6	15	3.9
<i>Europe</i>	75	39.1	163	42.9
<i>South-East Asia</i>	4	2.1	6	1.6
<i>Western Pacific</i>	58	30.2	32	8.4
<i>Not Reported</i>	1	0.5	0	0.0
Feature of Assays				
<i>RDT</i>	103	53.6	17	4.5
<i>Non-RDT</i>	89	46.4	363	95.5
Antibody Targets				
<i>Spike</i>	55	28.6	48	12.6
<i>Nucleocapsid</i>	37	19.3	37	9.7
<i>Multiplex Targets^a</i>	38	19.8	171	45.0
<i>Unknown</i>	62	32.3	124	32.6
Isotypes				
<i>IgG-only</i>	52	27.1	149	39.2
<i>IgG and IgM</i>	103	53.6	31	8.2
<i>Total Antibody (IgG, IgM, IgA)</i>	22	11.5	38	10.0
<i>Other Combinations^{b/}</i>				
<i>Not Reported</i>	15	7.8	162	42.6
Assay Sn. and Sp.				
Manufacturer/developer reported	91	47.4	124	32.6
Third-party validated	118	61.5	-	-
<i>Australia NRL</i>	16	8.3	-	-
<i>Australia Doherty</i>	18	9.4	-	-
<i>US FDA</i>	57	29.7	-	-
<i>FIND Diagnostic</i>	30	15.6	-	-
<i>Netherland CIDC</i>	26	13.5	-	-
<i>Other groups</i>	94	49.0	-	-
Emergency Use ^c				
<i>Yes</i>	57	29.7	-	-

No	135	70.3	-	-
----	-----	------	---	---

Note: ^a Multiplex targets indicate the assay detects more than one targets on the SARS-CoV-2 virus; the multiplex detection combinations include spike-whole virus antigen, spike-nucleocapsid, nucleocapsid-spike-envelope protein.

^b Other test isotypes include IgM-only, IgA-only, IgM and IgA, and other not-specified isotype combinations.

^c Manufacturer reported test performance met the WHO standards for Emergency Use Authorizations for COVID-19 serological tests: sensitivity minimum 90.0%, specificity minimum 97.0%.

Table 2. Predictors of assay Sn. and Sp. estimated with mixed-effect beta regression (N = 192)

Fixed effects	Sensitivity			Specificity		
	Difference in performance against manufacturer value ^a	Absolute performance value ^b	p ^c	Difference in performance against manufacturer value ^b	Absolute performance value ^a	p ^c
	[95% CI]	[95% CI]		[95% CI]	[95% CI]	
Source of Evaluation						
<i>Manufacturer</i>	<i>ref.</i>	93.6% [90.6, 95.7%]	<0.001 *	<i>ref.</i>	98.5% [97.8, 99.0%]	<0.001 *
<i>Independent</i>	3.3% [2.7, 3.4%]	90.3% [87.8, 92.3%]	0.001 *	0.2% [-0.1, 0.4%]	98.3% [97.8, 98.7%]	0.247
<i>Third Party's Lab</i>	1.0% [0.1, 1.4%]	92.6% [90.5, 94.3%]	0.289	0.9% [0.9, 0.9%]	97.6% [96.9, 98.2%]	0.000 *
<i>NRL</i>	-2.2% [-2.3, -1.8%]	95.8% [92.9, 97.5%]	0.207 *	4.2% [2.7, 6.4%]	94.4% [91.3, 96.4%]	<0.001 *
<i>US FDA</i>	-2.2% [-3.6, -1.3%]	95.8% [94.2, 97.0%]	0.038 *	0.4% [0.4, 0.4%]	98.1% [97.3, 98.6%]	0.047 *
<i>FIND Diagnostic</i>	18.6% [14.6, 22.8%]	75.0% [67.8, 81.1%]	<0.001 *	0.9% [0.6, 1.3%]	97.6% [96.4, 98.4%]	0.008 *
<i>Netherland CIDC</i>	-0.2% [-0.3, 0.0%]	93.8% [90.5, 96.0%]	0.825	0.5% [0.4, 0.7%]	98.0% [97.0, 98.7%]	0.060
<i>Doherty</i>	2.7% [1.5, 4.5%]	90.9% [86.1, 94.1%]	0.055	0.8% [0.4, 1.5%]	97.7% [96.2, 98.6%]	0.037 *

Note.

^a *Coefficients derived from the model were in log-odds formats, which were then converted to percentages for absolute performance value estimates.*


^b *Difference in performance matrix against manufacturer value was estimated using bootstrapping with 10000 iterations.*

^c *Corresponds to the significant level of p<0.05; p attaches to absolute performance values.*


The mixed beta regression model bounded between 0-100%, clustering assay performance data in serological assays groups.

^d *Assay features of isotype, test type, antibody targets, multiplex detection, and time to result were fitted as covariates to adjust outputs.*


Figure 1




a) Manufacturer reported Sn. and Sp.




b) Third-party validated Sn. and Sp.



c) Independent groups evaluated Sn. and Sp.






Times Reported



Test Type



- (A) Abbott Laboratories Architect SARS-CoV-2 IgG Test;
 (B) EUROIMMUNAG Anti-SARS-CoV-2 ELISA (IgG) Test;
 (C) Roche Diagnostics IgG, gM, IgA Elecsys®Anti-SARS-CoV-2 N Test;
 (D) DiaSorin SpA Liaison SARS-CoV-2 S1/S2 IgG Test; and
 (E) Beijing Wantai Biological Wantai SARS-CoV-2 Total Ab ELISA Test.



- 10% error in Sn.
- 5% error in Sp.
- + 5% error in Sn.
+ 0% error in Sp.
- + 10% error in Sn.
+ 3% error in Sp.